INDICATION CRENESSITY (crinecerfont) is indicated as adjunctive treatment to glucocorticoid replacement to control androgens in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH).

This site is intended for US healthcare professionals only.
Crenessity logo, click to visit homepage
DEDICATED SUPPORT FOR YOU AND YOUR PATIENTS

Discover Neurocrine
Access Support

A free comprehensive program created to support you and your patients prescribed CRENESSITY, ensuring that you can focus on what really matters

Your Care Coordinator, backed by a team, is available to assist you and your patient every step of the way, providing personalized, one-on-one guidance to access CRENESSITY and answering any questions you may have.

For you: qualified clinical pharmacists trained in CAH to partner with you on your patients' care plans.

For your staff: dedicated Care Coordinator to help provide comprehensive assistance navigating the insurance process and financial support options for patients

For your patients: personalized support throughout their CAH and CRENESSITY journey, ensuring they receive necessary information and partnership every step of the way

With Neurocrine Access Support for CRENESSITY, our goal is to ensure there are no access barriers to your patients starting and staying on treatment.

You can prescribe with confidence knowing our dedicated Support Program will help your patients get timely access to CRENESSITY with most patients paying $10 or less a month.*

Financial support options

With the CRENESSITY Savings Program, your commercially insured patients may pay as little as $0 for their prescription.1

For patients with a delay in coverage for treatment initiation, our QuickStart Program offers a free 30-day supply of CRENESSITY.*

Our Patient Assistance Program (PAP) is designed to assist those without insurance, those whose insurance does not cover CRENESSITY, or those who cannot afford their copay or coinsurance. PAP provides CRENESSITY at no cost.*

Learn more about Neurocrine Access Support
  • *Subject to eligibility; additional terms and conditions apply.

Dosing

Review the dosing and administration information for CRENESSITY.

Get in Touch

Sign up to schedule a call or visit with a Neurocrine representative.

CAH=congenital adrenal hyperplasia; GC=glucocorticoid.

INDICATION

CRENESSITY (crinecerfont) is indicated as adjunctive treatment to glucocorticoid replacement to control androgens in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH).

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

CRENESSITY is contraindicated in patients with hypersensitivity to crinecerfont or any excipients of CRENESSITY.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions. A hypersensitivity reaction, including throat tightness, angioedema, and generalized rash, occurred in a subject after 3 days of treatment with CRENESSITY. If a clinically significant hypersensitivity reaction occurs, initiate appropriate therapy and discontinue CRENESSITY.

Risk of Acute Adrenal Insufficiency or Adrenal Crisis with Inadequate Concomitant Glucocorticoid Therapy. Acute adrenal insufficiency or adrenal crisis, which is potentially life-threatening, can occur in patients with underlying adrenal insufficiency who are on inadequate daily glucocorticoid doses, especially in situations associated with increased cortisol need, such as acute intercurrent illness, serious trauma, or surgical procedures. Continue glucocorticoids upon initiation of and during treatment with CRENESSITY. Do not reduce the glucocorticoid dose below the dose required for cortisol replacement. Patients should continue to use stress dosing of glucocorticoids in cases of increased cortisol need.

ADVERSE REACTIONS

In adult patients, the most common adverse reactions (at least 4% for CRENESSITY and greater than placebo) are fatigue, headache, dizziness, arthralgia, back pain, decreased appetite, and myalgia.

In pediatric patients, the most common adverse reactions (at least 4% for CRENESSITY and greater than placebo) are headache, abdominal pain, fatigue, nasal congestion, and epistaxis.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088.

Dosage Forms and Strengths:

CRENESSITY is available in 50 mg and 100 mg capsules, and as an oral solution of 50 mg/mL.

Please see full Prescribing Information.